Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Metastatic Castrate-Resistant Prostate Carcinoma (mCRPC)”

74 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 74 results

Testing effectiveness (Phase 2)Ended earlyNCT02146833
What this trial is testing

SHIP (Selinexor in Hormone Insensitive Prostate Cancer)

Who this might be right for
Prostate Cancer
Karyopharm Therapeutics Inc 20
Testing effectiveness (Phase 2)WithdrawnNCT02035124
What this trial is testing

Cabazitaxel and BKM120 in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel

Who this might be right for
Advanced Prostate Cancer
SCRI Development Innovations, LLC
Large-scale testing (Phase 3)Looking for participantsNCT06629779
What this trial is testing

Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

Who this might be right for
Metastatic Castration-Resistant Prostate Cancer
Pfizer 900
Early research (Phase 1)Study completedNCT05177042
What this trial is testing

Trial of ARV-110 and Abiraterone in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Who this might be right for
Prostate Cancer Metastatic
Arvinas Androgen Receptor, Inc. 45
Testing effectiveness (Phase 2)WithdrawnNCT05191017
What this trial is testing

Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC

Who this might be right for
Prostate CancerProstatic CancerCancer of Prostate+5 more
Nuvation Bio Inc.
Testing effectiveness (Phase 2)Looking for participantsNCT04071236
What this trial is testing

Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy

Who this might be right for
Metastatic Castration-Resistant Prostate CarcinomaMetastatic Malignant Neoplasm in the BoneMetastatic Malignant Neoplasm in the Lymph Nodes+1 more
National Cancer Institute (NCI)
Post-approval studies (Phase 4)Looking for participantsNCT06099093
What this trial is testing

Pilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide Tetraxetan

Who this might be right for
Prostate CancerMetastatic Castration-resistant Prostate CancerMetastatic Castration-resistant Prostate Carcinoma
Brigham and Women's Hospital 30
Testing effectiveness (Phase 2)Study completedNCT04495179
What this trial is testing

AZD4635 With Durvalumab and With Cabazitaxel and Durvalumab in Patients With mCRPC.

Who this might be right for
Progressive Metastatic Castrate-Resistant Prostate Cancer
AstraZeneca 30
Early research (Phase 1)Study completedNCT02826772
What this trial is testing

Safety, Tolerability, and PK of GT0918 (Proxalutamide) in Subjects With Metastatic Castrate Prostate Cancer

Who this might be right for
Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Suzhou Kintor Pharmaceutical Inc, 40
Large-scale testing (Phase 3)Ended earlyNCT01083615
What this trial is testing

A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Who this might be right for
Castrate-Resistant Prostate CancerHormone Refractory Prostate Cancer
Achieve Life Sciences 14
Testing effectiveness (Phase 2)Study completedNCT01818986
What this trial is testing

Sipuleucel-T and Stereotactic Ablative Body Radiation (SABR) for Metastatic Castrate-resistant Prostate Cancer (mCRPC)

Who this might be right for
Metastatic Castrate-resistant Prostate CancermCRPC
University of Texas Southwestern Medical Center 20
Not applicableStudy completedNCT04516161
What this trial is testing

EPIX, a Study to Gather More Information About Characteristics of Patients and Other Factors Which May Contribute to Survival Over a Long Period of Time in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Treated With Radium-223 (Xofigo)

Who this might be right for
Metastatic Castration Resistant Prostate Cancer (mCRPC)
Bayer 1,180
Testing effectiveness (Phase 2)Study completedNCT01549951
What this trial is testing

Study to Investigate the Effects of Orteronel on the QT/QTc Interval in Patients With Metastatic Castration-Resistant Prostate Cancer

Who this might be right for
Prostate Cancer
Millennium Pharmaceuticals, Inc. 50
Early research (Phase 1)Study completedNCT02705469
What this trial is testing

ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer

Who this might be right for
Metastatic Castration-Resistant Prostate Cancer
Zenith Epigenetics 44
Testing effectiveness (Phase 2)Ended earlyNCT01681433
What this trial is testing

OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone

Who this might be right for
Prostate CancerMetastatic Castrate-Resistant Prostate CancerPSA
Costantine Albany 72
Testing effectiveness (Phase 2)Study completedNCT02463799
What this trial is testing

Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC

Who this might be right for
Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 36
Testing effectiveness (Phase 2)Study completedNCT03899467
What this trial is testing

The Safety and Tolerability of GT0918 in Subjects With mHSPC and mCRPC

Who this might be right for
Metastatic Castrate Resistant Prostate Cancer (mCRPC)Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Suzhou Kintor Pharmaceutical Inc, 61
Post-approval studies (Phase 4)Active Not RecruitingNCT04597125
What this trial is testing

RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhibitors) in Patients With Prostate Cancer That Has Spread to the Bones (mCRPC, Metastatic Castration-Resistant Prostate Cancer)

Who this might be right for
Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Bayer 654
Testing effectiveness (Phase 2)Looking for participantsNCT07002320
What this trial is testing

Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancer

Who this might be right for
Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
Institute of Cancer Research, United Kingdom 78
Testing effectiveness (Phase 2)Study completedNCT01360840
What this trial is testing

EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer

Who this might be right for
Prostate Cancer Metastatic
EMD Serono 180
Load More Results
90